Small Molecules, Biologics, Antibody Therapy

Baili Pharmaceutical is a comprehensive pharmaceutical enterprise that has developed end-to-end capabilities in early research and development, clinical development, manufacturing, and commercialization since its founding in 1996. The company focuses on addressing unmet clinical needs in the global biopharmaceutical sector, with a robust research and development portfolio that includes small molecule chemical drugs, large molecule biological drugs, and antibody-drug conjugates (ADCs). Baili Pharmaceutical leverages an integrated approach that encompasses the entire lifecycle of drug development, from intermediates and active pharmaceutical ingredients to formulations, thereby enhancing its operational efficiency and market reach.

The company has established a strong research and development framework, particularly in the oncology field, with its U.S. subsidiary, SystImmune, dedicated to pioneering innovative antibody drugs and ADCs. In China, Baili Pharmaceutical and its subsidiary, Baili-Bio, focus on developing both innovative and generic drugs, particularly in areas such as pediatrics, anesthesia, critical care, and oncology. Baili Pharmaceutical's commitment to innovation has earned it recognition as a national high-tech enterprise and a leader in technological innovation, reflecting its dedication to improving drug accessibility and providing breakthrough therapies for cancer patients globally.

China

四川百利天恒药业股份有限公司 百利药业是一家集研发、生产、营销为一体的现代化高新技术企业。拥有2个新药研发中心、1个抗体及ADC药物生产企业、1个化学中间体生产企业及1个化学原料药生产企业、2个化学。

Cancer

No. 1, Building 1, No. 161 Baili Road, Cross-Strait Science and Technology Park, Wenjiang District, Chengdu City

Baili Pharmaceutical

Company Details